Product Information
PRIFTIN 150 MG TABLET is a brand product labeled by Sanofi-Aventis U.S. LLC, priced at $4.8280 per EA under NDC 00088210224. Its NADAC has been published 359 times since Nov 20, 2019.
FDA first approved this application on Jun 22, 1998. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
150 mg/1
Manufacturer
Sanofi-Aventis U.S. LLCNDC
00088210224
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
RIFAPENTINEApproval Type
New Drug (NDA)
FDA Application
NDA021024FDA Approved
6/22/1998
TE Code
AB
On Market Since
2/8/2017
Pharmacological Classes
Price Statistics
The NADAC for PRIFTIN 150 MG TABLET has been published 359 times since Nov 20, 2019, and over the history we have for it it has risen 32.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $4.8280 per EA |
|---|---|
| All-time high | $4.8468 (May 13, 2026) |
| All-time low | $3.6468 (Nov 20, 2019) |
| 52-week high | $4.8468 |
| 52-week low | $4.7508 |
| Median price | $4.4322 |
| Average price | $4.3670 |
| Largest weekly change | +5.4% (Jan 15, 2020) |
| Weeks tracked | 359 |
| Tracking since | Nov 20, 2019 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the rifapentine market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Sanofi-Aventis U.S. LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
rifapentine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of PRIFTIN 150 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for PRIFTIN 150 MG TABLET, manufactured by Sanofi-Aventis U.S. LLC, is $4.8280 per EA (NDC 00088210224), effective Sep 30, 2026.
How has the price of PRIFTIN 150 MG TABLET changed over time?
Over the history we have for it, the NADAC for PRIFTIN 150 MG TABLET has risen 32.4%. It has been tracked across 359 weekly CMS publications since Nov 20, 2019.
What are the highest and lowest recorded NADAC prices for PRIFTIN 150 MG TABLET?
Since Nov 20, 2019, the NADAC for PRIFTIN 150 MG TABLET has ranged from a low of $3.6468 (Nov 20, 2019) to a high of $4.8468 (May 13, 2026), with a median of $4.4322 per EA.
Are there cheaper alternatives to PRIFTIN 150 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of PRIFTIN 150 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures PRIFTIN 150 MG TABLET?
PRIFTIN 150 MG TABLET (NDC 00088210224) is labeled by Sanofi-Aventis U.S. LLC, and CMS classifies it as a brand product.